The results of a new study show that, when added to statin therapy, evolocumab reduced LDL cholesterol levels by 59% from baseline levels compared with placebo.
Adding evolocumab to statin therapy also significantly reduced the likelihood of cardiovascular events.
There was a 15% reduction in the risk of the primary composite endpoint of cardiovascular death, myocardial infarction, stroke, hospitalization for unstable angina, or coronary revascularization; and a 20% decrease in the risk of the key secondary endpoint of cardiovascular, myocardial infarction, or stroke.
The randomized, double-blind, placebo-controlled study included more than 27,000 patients with atherosclerotic cardiovascular disease and LDL cholesterol levels of 70 mg per deciliter or higher who were receiving statin therapy.
The study results, note the researchers, "show that patients with atherosclerotic cardiovascular disease benefit from the lowering of LDL cholesterol levels below current targets." The research, funded by Amgen, was presented Friday at the annual meeting of the American College of Cardiology in Washington, DC.